ACTA1 and hepatocellular carcinoma: To explore the mechanism of oxaliplatin resistance from the perspective of tumor microenvironment, immunohistochemical staining revealed the increased expression of α-SMA in HCC tissue from oxaliplatin-treated tumor mice in the same trend with the enhanced resistance to chemotherapy (Fig. 1a).